Edition:
India

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

51.67USD
15 Feb 2019
Change (% chg)

$0.84 (+1.65%)
Prev Close
$50.83
Open
$51.42
Day's High
$51.87
Day's Low
$50.93
Volume
3,307,877
Avg. Vol
3,162,490
52-wk High
$70.04
52-wk Low
$44.30

Select another date:

Sat, Feb 16 2019

Photo

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday.

Starboard gauges Bristol-Myers shareholder support for Celgene deal

Feb 15 Activist hedge fund Starboard Value LP has asked a proxy solicitor to probe the level of support among Bristol-Myers Squibb Co shareholders for the U.S. drug maker's $74 billion deal to buy Celgene Corp, people familiar with the matter said on Friday.

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Feb 15 Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

Celgene profit beats as psoriasis drug sales surge

Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla.

UPDATE 1-Celgene profit beats as psoriasis drug sales surge

Jan 31 Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla.

AbbVie not contemplating big deals - CEO

Jan 25 AbbVie Inc is not considering a big merger or an acquisition, Chief Executive Officer Richard Gonzalez said on Friday, allaying speculations of the company launching a bid for Bristol-Myers Squibb.

Bristol-Myers has Opdivo lung cancer setback as sales beat estimates

NEW YORK Bristol-Myers Squibb Co said on Thursday it pulled an application seeking U.S. approval for a combination of its drugs to treat lung cancer, even as it announced better-than-expected fourth-quarter earnings on strong sales of one of those medicines, the immunotherapy Opdivo.

UPDATE 2-Bristol-Myers has Opdivo lung cancer setback as sales beat estimates

NEW YORK, Jan 24 Bristol-Myers Squibb Co said on Thursday it pulled an application seeking U.S. approval for a combination of its drugs to treat lung cancer, even as it announced better-than-expected fourth-quarter earnings on strong sales of one of those medicines, the immunotherapy Opdivo.

Bristol-Myers pulls U.S. application for combo lung cancer treatment

NEW YORK, Jan 24 Bristol-Myers Squibb Co on Thursday said it withdrew its application seeking U.S. approval for a combination of its blockbuster cancer immunotherapy drugs Opdivo and Yervoy as an initial treatment for advanced lung cancer while the drugmaker works to collect more data.

Select another date: